Background We investigated the impact of early‐(E‐CMV) and late onset (L‐CMV)
cytomegalovirus disease on the probability of graft rejection, graft failure, mortality, and …

Background Cytomegalovirus (CMV) disease typically occurs during the first year after solid
organ transplantation, after cessation of antiviral prophylaxis. CMV occurring after the first …

Background Cytomegalovirus (CMV) remains a significant contributor to morbidity and
mortality following solid organ transplantation (SOT). While recurrent infection occurs in up …

Cytomegalovirus (CMV) infection has a direct effect on morbidity in solid organ
transplantation patients, and indirect effects related to the development of opportunistic …

Efforts to prevent relapsed cytomegalovirus (CMV) disease among solid organ transplant
(SOT) recipients present clinical challenges. Historically, SOT recipients treated with short …

INTRODUCTION: Despite recent advances in prevention and treatment, cytomegalovirus
(CMV) is still a major complication in transplant patients. This study sought to analyze the …

Purpose This study aimed to describe the cytomegalovirus (CMV) infection rate,
rehospitalizations, and comorbidities following allogeneic hematopoietic stem cell …

BACKGROUND: The strength of the assumed association of CMV and long term deleterious
events in solid organ transplant recipients (SOT) is controversial. OBJECTIVES: The aim of …

Background The frequency and significance of cytomegalovirus (CMV) infection in
seropositive (R+) heart transplant recipients (HTR) is unclear, with preventative …

We assessed the impact of antiviral prophylaxis and preemptive therapy on the incidence
and outcomes of cytomegalovirus (CMV) disease in a nationwide prospective cohort of solid …